California Public Employees Retirement System grew its stake in Epizyme, Inc. (NASDAQ:EPZM) by 2.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 135,500 shares of the biopharmaceutical company’s stock after buying an additional 2,900 shares during the period. California Public Employees Retirement System owned approximately 0.23% of Epizyme worth $2,046,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in EPZM. Legal & General Group Plc lifted its position in shares of Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in shares of Epizyme during the 1st quarter worth about $175,000. BB&T Securities LLC acquired a new position in shares of Epizyme during the 2nd quarter worth about $181,000. Trexquant Investment LP acquired a new position in shares of Epizyme during the 2nd quarter worth about $184,000. Finally, SG Americas Securities LLC lifted its position in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 6,072 shares during the last quarter. 72.20% of the stock is owned by institutional investors.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02.
In related news, Director David M. Mott acquired 200,000 shares of the business’s stock in a transaction on Monday, September 18th. The stock was purchased at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total transaction of $235,200.00. Following the sale, the insider now owns 22,228 shares of the company’s stock, valued at $348,535.04. The disclosure for this sale can be found here. Insiders have sold 45,000 shares of company stock valued at $733,950 over the last 90 days. Company insiders own 25.20% of the company’s stock.
Several equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research report on Thursday. Leerink Swann reissued an “outperform” rating and set a $22.00 price objective (down previously from $28.00) on shares of Epizyme in a research report on Thursday. Royal Bank Of Canada cut Epizyme from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $20.00 to $16.00 in a research report on Thursday. Cann reissued a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Thursday. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, October 16th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $22.67.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
What are top analysts saying about Epizyme Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme Inc. and related companies.